Study of MLN4924 in Adult Patients With Nonhematologic Malignancies

Advanced Nonhematologic Malignancies Clinical Trial

Official title:
An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Nonhematologic Malignancies

Status Completed

Clinical Trial Summary

This study is an open-label, multicenter, Phase 1, dose escalation study of MLN4924 in adult patients with nonhematologic malignancies. This study will be the first to administer MLN4924 in humans. The patient population will consist of adults with any form of nonhematologic malignancy for which standard, curative, life prolonging, or palliative treatment does not exist or is no longer effective.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Advanced Nonhematologic Malignancies
Neoplasms

Clinical Trial Details

NCT number	NCT00677170
Study type	Interventional
Source	Millennium Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	April 2008
Completion date	December 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01204073` - A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies	Phase 1
Completed	`NCT01899053` - A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies	Phase 1
Completed	`NCT02327169` - A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies	Phase 1
Withdrawn	`NCT01613261` - Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies	Phase 1